Your session is about to expire
← Back to Search
DPCP Ointment for Alopecia Areata
Study Summary
This trial will test a new ointment for treating hair loss due to alopecia areata. The ointment is applied topically, and the trial will measure the safety and effectiveness of the treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any immune system-modifying drugs in the last 3 months.I have not used minoxidil in the last 4 weeks.I have or am receiving cancer treatment, except for skin cancer, in the last 5 years.I have not used light treatments like PUVA or UVB in the last 6 weeks.I have extensive hair loss covering 76% to 99% of my scalp.I have a condition like anemia or thyroid disease that could worsen by joining this study.I have been treated with DPCP before.I have not used Anthralin in the last 6 weeks.I am older than 18 years.I am not pregnant and agree to use highly effective birth control.I do not have any serious infections, except for herpes simplex.I have a weakened immune system due to a transplant, chemotherapy, spleen removal, or HIV.I haven't used any skin creams or injections for my condition in the last 6 weeks.I have used a skin cream for immune system modulation in the last 6 weeks.You have had a problem with drugs or alcohol in the last five years.I have a skin infection related to hair follicles.I have lost less than 76% or more than 99% of my hair.I haven't taken any steroids or immunosuppressants in the last 3 months.
- Group 1: Diphenylcyclopropenone (DPCP) Ointment
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the risks associated with this care option?
"There is some evidence for the efficacy of this treatment from Phase 3 trials, as well as multiple rounds of data supporting safety, which gives it a score of 3 on our team's estimation."
How many people are being recruited for this clinical trial?
"The listing on clinicaltrials.gov says that the investigators are still looking for participants. This trial was first advertised on November 1st, 2019 and has been updated as recently as May 4th, 2022. They need 10 more patients at a single location."
Are people with the specified medical condition able to participate in this trial at this time?
"The listing for this clinical trial on clinicaltrials.gov shows that the study is actively recruiting patients. The first posting was on November 1st, 2019 and there have been edits as recently as May 4th, 2022."
Can you provide some contextual information about this proposed treatment?
"There are presently 2 concurrent clinical trials studying this intervention, 1 of which is in Phase 3. Most of the research for this treatment occurs in Minneapolis, Minnesota; however, there are 2 sites running these studies."
Share this study with friends
Copy Link
Messenger